Drug news
Ipsen sells Apokyn North America rights to Britannia Pharma
Ipsen has sold to Britannia Pharmaceuticals the development and marketing rights for Apokyn (apomorphine) in North America, where the drug is the only product indicated for the acute, intermittent treatment of hypomobility "off" episodes associated with advanced Parkinson's disease.